Cargando…

Sa127 AN IBD-RISK VARIANT IN PTPN2 PROMOTES CELLULAR UPTAKE OF SARS-COV-2, WHICH IS MITIGATED BY THE JAK INHIBITOR TOFACITINIB

Detalles Bibliográficos
Autores principales:	Spalinger, Marianne, Hai, Rong, Li, Jiang, Nordgren, Tara M., Tremblay, Michel L, Eckmann, Lars, Hanson, Elaine M., Scharl, Michael M., Wu, Xiwei, Boland, Brigid, McCole, Declan F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2021
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108197/ http://dx.doi.org/10.1016/S0016-5085(21)01740-6

Ejemplares similares

Identification of a Novel Susceptibility Marker for SARS-CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in Human/Mouse Cells
por: Spalinger, Marianne R., et al.
Publicado: (2020)

Sa1055: PERCEPTIONS OF ACCESSING CARE AMONG IBD PATIENTS DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Sa1061: CROSS-SECTIONAL AND LONGITUDINAL ASCERTAINMENT OF PATIENTS WITH IBD'S PERCEPTIONS AND EXPERIENCES DURING COVID-19: CLAPPED COVID-19
por: Lee, Hanbich, et al.
Publicado: (2022)

Sa081 FEAR OF COVID-19 AMONG IBD PATIENTS ACCORDING TO EMPLOYMENT STATUS, EDUCATION AND RESIDENCE AND COMPARED TO OTHER GI CONDITIONS
por: Lo, Bobby, et al.
Publicado: (2021)

Sa1050: COVID-19 VACCINATION RATES AND POST-VACCINATION INFECTION RISK IN IBD PATIENTS TREATED WITH DISEASE MODIFYING AGENTS: A RESEARCH NETWORK ANALYSIS
por: Chumbe, Julton Tomanguillo, et al.
Publicado: (2022)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients
por: Yilmaz, Bahtiyar, et al.
Publicado: (2018)

Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence
por: Spalinger, Marianne Rebecca, et al.
Publicado: (2022)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

Sa1059: SURVEILLANCE COLONOSCOPY METRICS HAVE IMPROVED FROM BEFORE THE PANDEMIC
por: Seoud, Talal M., et al.
Publicado: (2022)

Mo1087: MALADAPTIVE BEHAVIORS IN PERSONS WITH IBD DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE
por: Ricciuto, Amanda, et al.
Publicado: (2021)

Sa004 DECLINING COLORECTAL CANCER SCREENING IN THE AGE OF COVID-19
por: Torres, Jon Alexander, et al.
Publicado: (2021)

Sa1318: IMPACT OF OBESITY ON OUTCOMES ASSOCIATED WITH ACUTE ALCOHOLIC PANCREATITIS
por: Pellegrini, James R., et al.
Publicado: (2022)

Su1494: REDUCED SEROLOGICAL RESPONSE TO COVID-19 VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; EARLY RESULTS OF THE VARIATION STUDY (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV2-IMMUNISATION)
por: Doherty, Jayne, et al.
Publicado: (2022)

PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation
por: Spalinger, Marianne R., et al.
Publicado: (2018)

Su102 DIFFERENCES IN INTESTINAL EPITHELIAL GENE EXPRESSION MODULATES SARS-COV-2 INFECTION IN HUMAN IBD ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2021)

Sa1317: HYPERLIPASEMIA IS ASSOCIATED WITH INCREASED MORTALITY IN COVID-19 HOSPITALIZED PATIENTS: A RETROSPECTIVE STUDY
por: Elfert, Khaled, et al.
Publicado: (2022)

Sa1275: ASSOCIATED FACTORS WITH ACUTE DIARRHEA IN SARS-COV-2 INFECTION: A CASE-CONTROL STUDY
por: Tellez, Francisco A. Felix, et al.
Publicado: (2022)

Sa1064: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LOCAL REPORT
por: Tsipotis, Evangelos, et al.
Publicado: (2022)

Sa1273: ENTERIC NEURONAL VASOACTIVE INTESTINAL PEPTIDE MEDIATES SARS-COV-2 ASSOCIATED DIARRHEA
por: Balasubramaniam, Arun, et al.
Publicado: (2022)

Fr491 MULTIVARIABLE PREDICTION MODELS FOR HOSPITALIZATION, VENTILATION, AND DEATH FROM COVID-19 IN IBD PATIENTS
por: Sperger, John, et al.
Publicado: (2021)

Sa143 THE RISK OF COVID-19 IS HIGHER IN FEMALES USING PROTON PUMP INHIBITORS
por: Ghoneim, Sara, et al.
Publicado: (2021)

Sa1057: OUTCOMES AND MANAGEMENT OF ACUTE NECROTIZING PANCREATITIS DURING THE COVID-19 PANDEMIC
por: Smith, Zachary L., et al.
Publicado: (2022)

Sa1427: THE LONGTERM EFFECTS OF COVID-19 ON ELEVATED LIVER FUNCTION TESTS AND OUTCOMES
por: Shah, Pooja, et al.
Publicado: (2022)

Su1496: SARS-COV-2 INFECTION IN IBD: PANDEMIC WAVES AND PREDICTORS OF SEVERE OR PERSISTENT COVID-19
por: Taxonera, Carlos, et al.
Publicado: (2022)

Sa1067: INTERNATIONAL SURVEY ON SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 AND ACUTE PANCREATITIS CO-OCCURRENCE IN CHILDREN
por: Wilschanski, Michael, et al.
Publicado: (2022)

Sa1429: CLINICAL AND PREDICTIVE FACTORS ASSOCIATED WITH NEED FOR TRANSJUGULAR PORTOSYSTEMIC SHUNT (TIPS) REVISION
por: Healey, Marcus A., et al.
Publicado: (2022)

Sa1685: OBESITY AND OUTCOMES IN YOUNG PATIENTS HOSPITALIZED FOR COLORECTAL CANCER IN THE US, 2016-2018
por: Wang, Yichen, et al.
Publicado: (2022)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

Sa003 COVID-19 PANDEMIC AND REDUCTION OF COLORECTAL CANCER SCREENING RELATED PROCEDURES IN THE CZECH REPUBLIC
por: Suchanek, Stepan, et al.
Publicado: (2021)

Sa571 EVALUATION OF MENTAL STATE AND CLINICAL SYMPTOMS OF CORONAVIRUS PANDEMIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Tani, Mizuki, et al.
Publicado: (2021)

Sa112 VENTILATED N95 RESPIRATORS REDUCE CO2 REBREATHING AND HAVE BETTER ACCEPTABILITY
por: Chesta, Fnu, et al.
Publicado: (2021)

Sa078 CLINICAL AND LABORATORY MARKERS DO NOT PREDICT DEEP HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS
por: Sharma, Disha, et al.
Publicado: (2021)

Sa1049: IMPACT OF THE NOVEL COVID-19 VIRUS ON OUTCOMES OF GASTROINTESTINAL BLEEDING: A MULTICENTER STUDY
por: Chouhan, Vijit, et al.
Publicado: (2022)

Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Khan, Shahab R., et al.
Publicado: (2021)

EP1021: CHANGES IN THE NEEDS OF IBD PATIENTS FOR TREATMENT BEFORE AND AFTER THE COIVD19 EPIDEMIC (ANALYSIS USING TWITTER DATA)
por: Fuchigami, Ayako
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ae789qgal5gijdrkeuehpti6e